- PARABILIS MEDICINES FILES FOR IPO ON PROMISING CANCER THERAPY, REGENERON INVESTS $125M
What changed
$PBLS
- PARABILIS MEDICINES FILES FOR IPO ON PROMISING CANCER THERAPY, REGENERON INVESTS $125M
Regeneron agreed to a $75M private placement + $50M upfront. Lead candidate zolucatetide shows Phase 1 safety and Phase 2 efficacy in desmoid tumors. Company has $329M cash.